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Introduction
Malaria has posed a risk to human life since the origin of our 
species. Despite this long history, it was not until 1880 that 
French army surgeon Charles Louis Alphonse Laveran discov-
ered intraerythrocytic parasites in the blood of a patient with 
malaria1. Immediately following Laveran’s discovery, crucial 
aspects of this infection, including species classification and the 
details of the human–mosquito transmission cycle, were revealed2–6. 
These early studies shaped our understanding of the protozoan 
parasites of genus Plasmodium that cause malaria. In the 
complex life-cycle of Plasmodium spp., human infection begins 
with the bloodmeal of a female Anopheles mosquito. Parasites 
migrate to the liver, where they undergo a large, asymptomatic 
expansion, emerging to invade red blood cells and initiate 
asexual replication. A small fraction of these blood-stage para-
sites terminally differentiate into gametocytes that are taken 
up by the mosquito to complete sexual replication and begin 
the infection cycle anew. Five different species of Plasmodium 
cause the majority of human malaria: P. falciparum, P. knowlesi, 
P. malariae, P. ovale, and P. vivax. Malaria still accounts for an 
estimated 445,000 deaths and 216 million cases annually, and 
the majority of deaths result from infection with P. falciparum7.
Malaria deaths have declined in large part because of the 
development of effective antimalarial medicines. Beginning 
in the late 1940s, chloroquine was the standard treatment for 
uncomplicated malaria8. However, by the late 1950s and early 
1960s, chloroquine-resistant P. falciparum was observed 
throughout Southeast Asia, Oceania, and South America. Resist-
ance to chloroquine has since spread to nearly all areas of the 
world9. Subsequent resistance has developed to antimalarials 
such as sulfadoxine/pyrimethamine, mefloquine, halofantrine, 
and quinine10. Most recently, resistance to artemisinin-based 
combination therapies emerged in 2008 in parts of Southeast 
Asia and continues to spread11–19. Clinical artemisinin resistance 
manifests as a delayed clearance phenotype; that is, infection 
eventually resolves with treatment with artemisinin-based com-
bination therapy, but the time required for parasite clearance 
substantially increases14,20,21. This delayed clearance could con-
tribute to the even more troubling rise in multi-drug resistance, 
as parasites have gained both reduced artemisinin sensitivity22 
and resistance against partner drugs, such as piperaquine12,19. As 
multi-drug resistance spreads, there is an urgent need for new 
antimalarial agents to control malaria infections. Optimally, 
new antimalarials will overcome multi-drug resistance, will be 
highly safe for use in vulnerable populations (such as infants 
and pregnant women), and will target more than one life-cycle 
stage in order to break the cycle of transmission. In this brief 
review, we highlight promising novel antimalarials currently in 
development and introduce emerging drug targets that may be 
key to ongoing efforts to eliminate malaria worldwide.
Promising new antimalarials in development
Global efforts to end malaria have led to the development 
of promising compounds. At the forefront of antimalarial 
development is the Medicines for Malaria Venture (MMV), 
which was established in 1999 as a not-for-profit, public–private 
partnership. The current MMV portfolio contains many promising 
compounds at various stages of development (research, transla-
tional, product development, and access; https://www.mmv.org/ 
research-development/mmv-supported-projects). To illustrate 
the diversity of the current portfolio, a selection of the emerg-
ing antimalarials currently in development is discussed below 
(Table 1)23–29.







Target candidate profilesa Current status in MMV pipelineb
Artefenomel OZ439 Unknown Asexual parasite clearance; 
transmission blocking
Combined artefenomel–ferroquine is 
in the patient-exploratory stage
Cipargamin KAE609, 
NITD609
PfATP4, based on resistance 
screen mutations23
Asexual parasite clearance; 
transmission blocking
Patient-exploratory stage
DSM265 Not applicable Plasmodium DHODH24 Asexual parasite clearance; 
targeting liver schizonts
Patient-exploratory stage
Ferroquine SSR97193 Unknown Asexual parasite clearance; 
transmission blocking
Combined artefenomel–ferroquine is 
in the patient-exploratory stage
KAF156 GNF156 PfCARL25, PfACT, and PfUGT26, 
based on resistance screen 
mutations
Asexual parasite clearance; 
transmission blocking; 
targeting liver schizonts
Combined KAF156–lumefantrine is in 
the patient-exploratory stage




SJ733 (+)-SJ000557733 PfATP4, based on resistance 
screen mutations28,29
Asexual parasite clearance; 
transmission blocking
Human volunteer stage
Tafenoquine WR 238605, 
Etaquine





aAccording to Medicines for Malaria Venture (MMV) Target Candidate Profile classification.
bStatus as of 31 July 2018.
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Artefenomel and ferroquine
The current standard of care for malaria is combination 
therapy based on artemisinin, which is highly valued as a potent, 
rapidly active antiparasitic compound. Like artemisinin, synthetic 
ozonides contain an endoperoxide bond. A first-generation ozo-
nide, arterolane (OZ277), has already been licensed for clinical 
use in India as a combination therapy with piperaquine. However, 
concern has arisen that there may be a loss of potency against 
kelch13 mutant parasites, which are artemisinin resistant30–33. 
Other synthetic ozonides, including artefenomel (OZ439), have 
been developed34. Artefenomel displays activity in transmission- 
blocking assays in vitro35, and clinical studies support its use in 
a single-exposure combination therapy36. Unlike artemisinin’s 
peroxide bond, artefenomel’s peroxide bond is more stable and 
has an improved half-life in plasma: 23 hours compared with 
0.5 hours34. Promisingly, artemisinin-resistant mutants do not 
appear to be cross-resistant to artefenomel30,31, although some 
mutations in kelch13 may lead to partial cross-resistance30–33. 
Together, these properties support the continued efforts toward 
development and licensure of artefenomel for clinical use.
Ferroquine is a third-generation 4-aminoquinoline and a deriva-
tive of the antimalarial chloroquine. Although chloroquine 
resistance has spread to nearly all areas of the world, ferroquine 
efficacy is not impeded by chloroquine resistance mechanisms 
and resistance selection has not been observed in the laboratory37. 
Ferroquine also retains activity against parasites resist-
ant to chloroquine, mefloquine, quinine, and piperaquine38,39. 
An initial clinical study with ferroquine in combination with 
artesunate showed a high malaria cure rate, and treatment with 
ferroquine also displayed post-treatment prophylaxis activity 
for at least 2 months40. Recent phase 2 trials replaced artesunate 
with the more effective artefenomel40–42, and a combination of 
artefenomel and ferroquine therapy is in the patient-exploratory 
stage of the MMV portfolio.
DSM265
Plasmodium spp. depend on de novo pyrimidine synthesis 
because they lack pyrimidine salvage enzymes. An essential 
enzyme in the pyrimidine biosynthesis pathway is dihydroorotate 
dehydrogenase (DHODH). Large high-throughput screens were 
conducted to identify PfDHODH inhibitors43,44. These screens 
identified several classes of molecules that target DHODH, 
such as triazolopyrimidines, phenylbenzamides, ureas, and 
naphthamides44. One triazolopyrimidine that has potent activity 
against asexual and liver-stage parasites is DSM26545. DSM265 
selectively inhibits Plasmodium spp. DHODH enzymes over 
human orthologues24. DSM265 is currently in the patient-
exploratory stage of the MMV pipeline and exhibits promising 
single-dose efficacy. Interestingly, DSM265 is predicted to 
remain at therapeutic concentrations in humans for more than 
a week after a single dose because of its favorable pharmacoki-
netic properties45. DSM265 also has promising prophylactic 
activity, providing some protection against infection with a single 
dose up to 7 days before parasite challenge46,47. The single-dose 
efficacy of DSM265 makes it exceptionally promising for both 
prophylaxis and treatment of disease. Furthermore, the potency of 
DSM265 supports future development of compounds that target 
Plasmodium DHODH.
Cipargamin and SJ733
Cipargamin (KAE609), a spiroindolone, also has potent activity 
against blood-stage malaria parasites23,48. A recent phase 2 study 
used once-daily dosing of cipargamin for 3 days on 21 adults 
with either uncomplicated P. vivax or P. falciparum malaria49. 
Parasite clearance rates in this clinical study and in vitro are 
among the fastest of any antimalarial yet characterized23,49. 
Cipargamin likely targets the P-type Na+ ATPase, PfATP4, because 
resistance mutations have emerged23. PfATP4 appears to regulate 
parasite ion homeostasis, which is essential for survival, through 
active Na+ export50. Inhibition of PfATP4, through cipargamin 
treatment, perturbs ion homeostasis in the parasite and increases 
host cell membrane rigidity, resulting in blocked blood-stage 
development and transmission to mosquitoes28,29,50–52. Cipar-
gamin is currently in the patient-exploratory stage of the 
MMV portfolio; however, it is not the only PfATP4 inhibitor 
currently in development. A diverse range of compounds, includ-
ing spiroindolones23,51,53, pyrazoleamides29, aminopyrazoles53, 
dihydroisoquinolones28, and other compounds54, have been shown 
to target PfATP4. A dihydroisoquinolone that likely targets 
PfATP4, SJ733, is in the human volunteer stage of the MMV 
portfolio. Resistance selection with SJ733, like cipargamin, 
has generated point mutations, some unique to SJ733 
and not induced by cipargamin, in the pfatp4 gene28,29. The 
antimalarial properties of PfATP4 inhibitors, such as cipar-
gamin and SJ733, are exceptionally promising and support 
future development of compounds with this mechanism of 
action.
KAF156
A novel class of antimalarials, imidazolopiperazines, has 
recently emerged and been found to have potent asexual blood-
stage and liver-stage activity55,56. One such imidazolopiperazine, 
KAF156, is currently in the patient-exploratory stage of the 
MMV portfolio in combination with lumefantrine. Lumefan-
trine is a clinically approved partner agent; however, it has been 
modified to a new once-daily formulation for use with KAF156. 
In addition to displaying asexual blood- and liver-stage 
activity, KAF156 also inhibits the growth of sexual blood-
stage parasites, including mature gametocytes57. Therefore, 
KAF156 may be effective in preventing parasite transmission 
from humans to mosquitoes. The antimalarial mechanism of 
KAF156 is still unclear because resistance in vitro is thought to be 
indirectly mediated through mutation of pfcarl, pfact, and 
pfugt, which encode a conserved protein of unknown function, 
an acetyl-CoA transporter, and a UDP-galactose transporter, 
respectively25,26,55. Future studies may illuminate the parasiticidal 
mechanism of imidazolopiperazines, but this class of drugs has 
great potential in the treatment of acute disease and reduction of 
parasite transmission.
MMV048
Another novel chemical class of antimalarials, 2-aminopyrid-
ines, was identified to have potent single-dose activity against 
in vitro P. falciparum and in vivo P. berghei58. From this initial 
screen of 2-aminopyridines, compound 15 (now known as 
MMV048) was identified with robust antimalarial activity. A 
follow-up study with MMV048 replicated the potent in vitro 
and in vivo activity of asexual blood-stage malaria parasites and 
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also confirmed transmission-blocking and liver-stage activity27. 
Genomic and chemoproteomic approaches identified Plasmo-
dium phosphatidylinositol 4-kinase (PI4K) as the likely target 
of MMV04827. PI4K functions in membrane trafficking and 
membrane assembly during asexual blood-stages59. PfPI4K 
is likely essential during the asexual blood-stage because 
attempts to insert an early stop codon were unsuccessful59. The 
multi-stage antimalarial activity, prolonged half-life, and single-
dose efficacy of MMV048 make it a promising new antimalarial 
in the patient-exploratory stage of the MMV pipeline.
Tafenoquine
Although infection with P. falciparum represents the largest 
burden of malaria deaths, there is also a need to develop medi-
cines that prevent the relapse of P. vivax and P. ovale. Unlike 
P. falciparum, both P. vivax and P. ovale have a dormant liver- 
stage form called a hypnozoite. Hypnozoites can reactivate with-
out warning, leading to the onset of malarial symptoms. This 
dormant stage remains both a challenge to treat and a potent bar-
rier to malaria elimination. Tafenoquine, an 8-aminoquinoline, is 
currently under development for the prevention of P. vivax 
relapse. Tafenoquine has high activity as a single-dose treat-
ment and has promising anti-hypnozoite activity in humans60. 
However, tafenoquine has therapeutic restrictions similar to those 
of the current radical cure standard for P. vivax and P. ovale, 
primaquine, which might limit its therapeutic impact. Both 
primaquine and tafenoquine cause dose-dependent acute 
hemolytic anemia in individuals with glucose-6-phosphate 
dehydrogenase deficiency61,62. Because of its longer half-life, 
tafenoquine requires a higher glucose-6-phosphate dehydro-
genase activity threshold than primaquine; thus, a greater 
proportion of individuals will be ineligible for tafenoquine 
treatment and primaquine will still be needed63. In July 2018, 
the US Food and Drug Administration approved tafenoquine 
under the trade name Krintafel. Tafenoquine is the first new 
antimalarial in 60 years to prevent relapse of P. vivax. How-
ever, its limitations highlight the need for development of 
additional compounds that target relapsing malaria.
Emerging new antimalarial targets
Continued efforts to dissect the basic biology of the complex 
malarial organism have yielded new therapeutic targets for 
the development of antimalarials. The Plasmodium Genetic 
Modification Project (PlasmoGEM) (http://plasmogem.sanger.
ac.uk), a not-for-profit, open-access research resource, has 
advanced our understanding of Plasmodium by providing vec-
tors for genome-wide manipulation. PlasmoGEM contains over 
2,000 plasmids designed to tag or delete genes in P. berghei64. 
Provided without cost, these tools have been used in a recent 
large-scale knockout screen to identify essential genes. The 
essentiality of over 50% of the genome was tested in an in vivo 
mouse model of P. berghei infection65. Surprisingly, 44.9% of 
genes were found to be essential and an additional 18% showed 
reduced parasite blood-stage growth; therefore, 62.9% of genes 
are required in P. berghei for normal asexual growth65. The high 
percentage of essential genes and low functional redundancy 
suggest that Plasmodium may have considerably more drug 
targets than do bacteria, for example65. This genetic screen 
resulted in the identification of essential cellular processes in the 
parasite. Specific examples of pathways enriched with essential 
genes include glycosylphosphatidylinositol anchor biosynthesis, 
the mitochondrial tricarboxylic acid cycle, ubiquinone biosyn-
thesis, and isoprenoid biosynthesis65. From this genetic screen, 
a searchable phenotype database was built (http://plasmogem. 
sanger.ac.uk/phenotypes).
A large forward genetic screen in P. falciparum parasites 
recently identified more than 2,680 genes that are likely essen-
tial for asexual blood-stage growth66. When high-throughput 
piggyBac transposon insertional mutagenesis was used in com-
bination with quantitative insertion site sequencing67,68, the 
mutability and fitness cost of 5,399 genes were evaluated66. The 
AT-richness of the P. falciparum genome (>81%) is well suited 
for piggyBac transposon-based mutagenesis because of the high 
density of the tetranucleotide insertion target sequence TTAA66. 
To quantify gene essentiality, a mutagenesis index score and 
mutagenesis fitness score were calculated for each locus. 
Together, these two independent measures were used to classify 
a gene as likely essential or dispensable, and this methodology 
may be expanded to identify essential genes for other life-cycle 
stages66. The essential genes and pathways discovered in both 
the PlasmoGEM P. berghei screen65 and piggyBac transposon 
P. falciparum screen66 will supplement ongoing studies and 
likely initiate investigation into novel putative antimalarial 
targets.
A final strategy to identify possible new antimalarial targets is 
the resistance screen. Resistance screens challenge the malaria 
parasite with low levels of an antimalarial compound to hinder 
development. This can lead to in vitro evolution and selection 
for resistance mutations that relieve growth suppression. There-
fore, resistance screens can be used to discover both media-
tors of drug resistance and novel antimalarial drug targets22,69. 
Winzeler and colleagues recently performed a large resistance 
screen with 37 distinct compounds70. Whole genome sequenc-
ing of 262 compound-resistant parasite lines identified several 
candidate resistance mutations. Although the screen confirmed 
previously identified multi-drug resistance mechanisms and 
illuminated new drug target–inhibitor pairs, only two novel 
drug-resistance genes—pfabcI3 and pfaat170—were identified. 
Below, we highlight a few emerging antimalarial targets of 
particular promise (Figure 1).
PMIX and PMX
Two recent studies highlighted the importance of plasmep-
sins IX (PMIX) and X (PMX) for parasite development71,72. 
Plasmepsins comprise a family of 10 aspartic proteases in the 
P. falciparum genome. A number of studies have focused on 
the digestive vacuole plasmepsins I to IV (PMI to PMIV), 
including development of chemical inhibitors73–76. Subsequent 
functional genetic studies of PMI–PMIV revealed that they are 
not essential for parasite survival77. PMIX and PMX are expressed 
in asexual blood-stage parasites78. Conditional knockdown 
of PMIX in P. falciparum revealed that it is essential for red 
blood cell invasion71,72. PMX knockdown similarly interrupted 
red blood cell invasion but also revealed an additional require-
ment of PMX in red blood cell egress72. A recent study employed a 
combination of in vitro and in vivo rodent experiments to find that 
hydroxyl-ethyl-amine-based scaffold compound 49c (referred 
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Figure 1. Localization of antimalarial targets in the asexual parasite. Shown are parasite organelles, including the nucleus, apicoplast 
(AP), endoplasmic reticulum (ER), food vacuole (FV), rhoptries (RH), exonemes, and vesicles. The intraerythrocytic parasite is located within 
the parasitophorous vacuole (PV), which is delineated by the PV membrane (PVM), where both SUB1 and SERA6 are found during egress98. 
Rab11a likely localizes to vesicles, which it guides to target membranes. In the invading parasite, plasmepsin IX (PMIX) is found in the bulbs 
of RH and plasmepsin X (PMX) localizes to exonemes72.
to as 49c) inhibits both PMIX and PMX71. 49c is an effective 
inhibitor against P. falciparum in vitro and the rodent parasite 
Plasmodium berghei in vivo79,80. Treatment with 49c inhibits 
asexual, sexual, and liver-stage development, indicating that 49c 
or other PMIX or PMX inhibitors may have value to both treat 
symptomatic malaria and block transmission71. Together, these 
observations provide compelling evidence that PMIX and PMX 
are promising targets for antimalarial development.
Rab11a
In the recent P. berghei functional genetic screen, one of the 
cellular pathways most enriched with essential genes is that of 
isoprenoid biosynthesis65. A number of studies have previ-
ously highlighted the requirement of isoprenoid biosynthesis for 
P. falciparum asexual replication81–83. Isoprenoids are necessary 
for protein prenylation, the post-translational lipid modification 
of proteins. Because chemical inhibition of protein prenylation 
in the malaria parasite disrupts asexual parasite growth84–90, 
prenylated malarial proteins are potential antimalarial targets. 
Recent chemical labeling approaches have revealed that only 
15 to 19 proteins are prenylated in blood-stage malaria and a 
majority of these proteins are Rab GTPases91,92. Rab GTPases 
function in docking vesicles to membranes and their prenyla-
tion aids in association with target membranes93. Rab11a, a 
Rab GTPase, is expressed and prenylated in asexual blood-
stage malaria parasites91,92,94 and is essential for asexual parasite 
replication95. In the parasite, Rab11a functions as a mediator of 
PI4K signaling and is a binding partner of PI4K, the target of 
imidazopyrazines and MMV04827,59,96. Mutation of Rab11a 
confers resistance to the imidazopyrazine, KAI71559. Interest-
ingly, Rab11a has very low genetic diversity when sequenced 
in 2,000 Plasmodium clinical isolates, and only one non- 
synonymous mutation has been identified97. These features 
suggest that Rab11a may represent a promising target because 
of both its prenylation and interactions with essential signaling 
pathways within the parasite. Additional studies are needed to 
evaluate the biological roles of the remaining prenylated proteins 
in blood-stage malaria.
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SUB1 and SERA6
During asexual replication, the malaria parasite must exit the 
red blood cell before invading a new cell. This process, called 
egress, requires the rupture of both the parasitophorous vacuole 
membrane (PVM), which surrounds the parasite, and the red 
blood cell membrane (RBCM). Egress is protease dependent99, 
and recently two proteases—SUB1 and SERA6—were identified 
as mediators of PVM and RBCM rupture98. SUB1, a serine 
protease, moves to the parasitophorous vacuole before 
egress100–104 and cleaves multiple substrates100,103,105–107. One sub-
strate cleaved by SUB1 is SERA6108–110, a putative cysteine 
protease, which requires proteolytic processing by SUB1 to 
function98. P. falciparum parasites that lack SUB1 fail to rup-
ture the PVM, thus stalling parasite development98. Interestingly, 
parasites that lack SERA6 can rupture the PVM, but RBCM 
rupture does not occur98. Therefore, SUB1 and SERA6 have 
distinct roles in parasite egress. Because SUB1 and SERA6 are 
essential for asexual blood-stage growth and orthologues are 
found in other Plasmodium species98, compounds that inhibit 
these proteins may be useful in treating multiple types of malarial 
disease.
Discussion
Malaria continues to be a major global health concern. 
Plasmodium elimination will not be possible without substan-
tial ongoing efforts, including diagnostic testing and treatment of 
confirmed and asymptomatic infections, mosquito vector con-
trol, preventative therapies, and surveillance systems. Although 
all of these areas of malaria control are crucial, antimalarial drug 
discovery is among the most pressing because of the continued 
spread of antimalarial resistance. The MMV has focused its 
efforts on developing drugs that treat disease, prevent transmis-
sion, and provide chemoprotection. This multifaceted approach 
to the antimalarial development pipeline provides assurance that 
new antimalarials will contribute to broad approaches of malaria 
control.
Studies in basic parasite biology remain extremely impor-
tant to elimination efforts. Although the current antimalarial 
compounds under development have great potential, malaria 
control efforts will benefit from continued dissection of parasite 
biology. Ideally, new compounds will target proteins and 
pathways that are essential for parasite growth and transmis-
sion with diverse mechanisms of action. New antimalarials 
will almost certainly be employed in combination therapeutics, 
combining molecules of different chemical classes and with 
diverse mechanisms of action to slow the development of multi-
drug resistance. Novel drug targets will be uncovered through 
multiple approaches, such as large-scale genetic and resistance 
screens. A deeper understanding of essential parasite biology 
will also aid in other aspects of malaria control, including 
mosquito vector control, advancement of diagnostic tests, and 
development of preventative therapies. To date, Plasmodium 
has successfully adapted to sequential drug selective pressure in 
the field. However, the remarkable successes of recent efforts to 
develop new antimalarials and identify drug targets suggest an 
optimistic future in treatment of disease, prevention of transmis-
sion, and protection against infection.
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